Mark S. Diamond
University of Pennsylvania · 42 works · 4,596 citations · h-index 11
Top works
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- A critical function for type I interferons in cancer immunoediting
- Blocking Monoclonal Antibodies Specific for Mouse IFN- α / β Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection
- Interferon-γ and Cancer Immunoediting
- Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
- Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
- Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming
- Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
- Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.
- Immune Checkpoint Inhibitors in Cardiac Sarcoma
- SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).
- Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database
- Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial
- 628 First-in-human study of CDR404, a novel bivalent and bispecific, antibody-derived, T cell engager in MAGE-A4-positive advanced solid cancers
- Abstract A123: Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients
- Erratum: Corrigendum: A critical function for type I interferons in cancer immunoediting
- Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
- Supplementary Figure 2 from Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming
- Supplementary Figure 4 from Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming